Avotres Presents Clinical Data for AVT001, a Novel Dendritic Cell Vaccine for Treatment of Type 1 Diabetes at ADA2023
• AVT001 is an investigational autologous dendritic cell-based vaccine for the treatment of new onset T1D CEDAR KNOLLS, NJ, UNITED STATES, July 19, 2023 /EINPresswire.com/ -- Avotres Inc., a clinical stage biotechnology company developing …